ASTELLAS PHARMA LTD.
Get an alert when ASTELLAS PHARMA LTD. files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£27m
+2.3% vs 2025
Employees
109
-1.8% lowest in 3 filed years
Profit before tax
£10m
-7.5% vs 2025
Net assets
3-year trend · vs Consumer Discretionary median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2026-03-31
| Metric | Trend | 2024-03-31 | 2025-03-31 | 2026-03-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £165,077,000 | £202,156,000 | £217,419,000 | +7.6% | |
| Operating profit | £7,021,000 | £8,547,000 | £8,524,000 | -0.3% | |
| Profit before tax | £8,405,000 | £10,777,000 | £9,970,000 | -7.5% | |
| Net profit | £6,184,000 | £8,318,000 | £7,453,000 | -10.4% | |
| Cash | — | — | — | — | |
| Total assets less current liabilities | £32,817,000 | £26,226,000 | £27,143,000 | +3.5% | |
| Net assets | £32,757,000 | £26,114,000 | £26,710,000 | +2.3% | |
| Equity | £32,757,000 | £26,114,000 | £26,710,000 | +2.3% | |
| Average employees | 110 | 111 | 109 | -1.8% | |
| Wages | £11,055,000 | £11,289,000 | £11,383,000 | +0.8% | |
| Directors' remuneration | £539,000 | £435,000 | £652,000 | +49.9% | |
| Directors' pension contributions | £39,000 | £44,000 | £40,000 | -9.1% | |
| Highest paid director | £370,000 | £405,000 | £446,000 | +10.1% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Operating margin | 4.3% | 4.2% | 3.9% | |
| Net margin | 3.7% | 4.1% | 3.4% | |
| Return on capital employed | 21.4% | 32.6% | 31.4% | |
| Gearing (liabilities / total assets) | 74.6% | 83.4% | 83.9% | |
| Current ratio | 1.33x | 1.18x | 1.18x | |
| Interest cover | 4.67x | 11.72x | 10.28x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- ASTELLAS PHARMA LTD. 2005-08-19 → present
- YAMANOUCHI PHARMA LTD. 1994-03-01 → 2005-08-19
- BROCADES (GREAT BRITAIN) LIMITED 1964-01-10 → 1994-03-01
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young Chartered Accountants
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The company's financial statements are prepared using the going concern basis of accounting; the Directors have concluded that, based on future forecasts prepared for a period of 12 months from the date of the audit report and stress tests as well as reverse stress test of these forecasts and the provision of financial support by the parent company, Astellas B.V., there are no material uncertainties related to events or conditions that may cast significant doubt about the ability of the company to continue as a going concern.”
Significant events
- “The directors have approved an interim dividend of £7,000,000 on 29 June 2026”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 28 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BORENSTEIN, Rowena | Director | 2021-04-01 | Sep 1970 | Canadian |
| MCKAY, Barnaby George Robert | Director | 2026-01-01 | Apr 1977 | British |
| RAMIREZ, Sandra Patricia | Director | 2026-01-01 | Aug 1966 | Colombian |
Show 28 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| TURNBULL, Robert Harvey | Secretary | 2005-03-01 | 2012-11-23 |
| SISEC LIMITED | Corporate Nominee Secretary | — | 2005-03-01 |
| ALDEMIR-CEVIK, Dilek | Director | 2020-09-14 | 2022-09-08 |
| BALLERO, Philippe Andre Pierre | Director | 1998-03-01 | 2001-10-01 |
| BRITSTRA, Arend Gerrit | Director | 2000-01-01 | 2000-08-01 |
| CROOKS, Michael John | Director | 2012-01-01 | 2017-05-31 |
| DAVIS, Jacqueline Sarah | Director | 2020-04-01 | 2026-01-01 |
| DE HEUS, Johannes Adrianus | Director | 2000-08-01 | 2002-11-01 |
| FERGUSON, Dudley Henry | Director | — | 2007-09-01 |
| HALL, Ian Michael | Director | 2016-04-01 | 2020-09-13 |
| HUIBERTS, Henricus Johannes | Director | — | 1998-09-01 |
| INOUE, Masakatsu | Director | — | 1994-01-01 |
| ISHII, Yasuo | Director | 2001-01-01 | 2004-06-30 |
| JANSEN VAN RENSBURG, Eugene Theodorus | Director | 2015-07-20 | 2018-07-02 |
| KINOSHITA, Seiji | Director | 2007-09-01 | 2010-07-01 |
| KOCKELKOREN, Wilhelmus Jacques Josephus | Director | 2004-09-01 | 2006-03-30 |
| MAKWANA, Amit | Director | 2007-09-01 | 2011-06-12 |
| NOGAWA, Hiroshi | Director | 2006-03-30 | 2007-09-01 |
| PAASMAN, Arend | Director | — | 1998-03-01 |
| PEARSON, Adam John | Director | 2019-04-01 | 2020-03-31 |
| READ, Martin Anthony, Dr | Director | 2021-04-01 | 2025-06-30 |
| SANTHARAM, Yagnaram | Director | 2022-09-09 | 2024-09-30 |
| SANZ, Jose Maria, Dr | Director | 2018-07-02 | 2019-03-31 |
| SCHULZE, Daniel Benjamin Matthias | Director | 2016-04-04 | 2018-03-12 |
| STANDER, Nicolaas Jacobus | Director | 2015-03-10 | 2015-07-20 |
| TAKAHASHI, Shigekazu | Director | — | 2001-01-01 |
| TURNBULL, Robert Harvey | Director | — | 2016-04-01 |
| WITTEVEEN, Douwe Wybe | Director | 1998-09-01 | 2000-01-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Astellas Pharma Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2022-02-23 |
| Astellas Pharma Europe Ltd. | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 206 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-08-07 | AA | accounts | Accounts with accounts type full | |
| 2026-03-18 | AP01 | officers | Appoint person director company with name date | |
| 2026-03-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-30 | AP01 | officers | Appoint person director company with name date | |
| 2026-01-27 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-18 | TM01 | officers | Termination director company with name termination date | |
| 2025-08-01 | AA | accounts | Accounts with accounts type full | |
| 2025-02-25 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-12-19 | AA | accounts | Accounts with accounts type full | |
| 2024-10-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-02-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-12-05 | CH01 | officers | Change person director company with change date | |
| 2023-10-17 | AA | accounts | Accounts with accounts type full | |
| 2023-02-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-12-22 | AA | accounts | Accounts with accounts type full | |
| 2022-12-05 | AD01 | address | Change registered office address company with date old address new address | |
| 2022-10-03 | AP01 | officers | Appoint person director company with name date | |
| 2022-09-15 | TM01 | officers | Termination director company with name termination date | |
| 2022-03-30 | AA | accounts | Accounts with accounts type full | |
| 2022-02-23 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 6
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.